Ein guter Preis.  Online

Einzelheiten zu den Produkten

Created with Pixso. Zu Hause Created with Pixso. Produits Created with Pixso.
Brust-Lungenkrebs-Medikamente
Created with Pixso. Aprepitant Injectable Emulsion 130mg Vial 18ml Dosage for Chemotherapy Induced Nausea Vomiting Prevention NK1 Receptor Antagonist

Aprepitant Injectable Emulsion 130mg Vial 18ml Dosage for Chemotherapy Induced Nausea Vomiting Prevention NK1 Receptor Antagonist

Markenname: Sichuan Kelun Pharmaceutical Co., Ltd.
Modellnummer: Aprepitant KL-20253052
Mindestbestellmenge: Verhandelbar
Preis: Please contact a specialist WhatsApp:55342706
Lieferzeit: Verhandelbar
Zahlungsbedingungen: Western Union, MoneyGram, T/T.
Detailinformationen
Herkunftsort:
Chengdu, Sichuan, China
Zertifizierung:
NMPA/GMP
Wirkstoff:
Aprepitante
Spezifikation:
18 ml: 130 mg
Dosierung:
130 mg intravenöse Infusion über 30 Minuten
Lagertemperatur:
Unter 30 °C
Haltbarkeit:
24 Monate
Genehmigungscode:
H20253052
Verpackung Informationen:
Verhandelbar
Versorgungsmaterial-Fähigkeit:
Verhandelbar
Hervorheben:

NK1 Receptor Antagonist CINV

,

Injectable Neurokinin 1 Blocker

,

Delayed Phase CINV Prevention

Produktbeschreibung
Aprepitant 18ml:130mg [Product Name] Generic Name: Aprepitant Specification: 18ml:130mg [Active Ingredient] Aprepitant [Indications] Prevention of acute and delayed CINV with highly and moderately emetogenic chemotherapy. Triple regimen with 5-HT3 antagonist and dexamethasone. [Mechanism of Action] Selective high-affinity NK1 receptor antagonist blocking substance P-mediated emetic reflex in the CNS. Superior delayed-phase CINV control. [Dosage] 130mg IV infusion over 30 min